We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Loses Challenge to Impax-Endo Opioid Agreement
FTC Loses Challenge to Impax-Endo Opioid Agreement
An administrative law judge tossed out the Federal Trade Commission’s complaint challenging an agreement between Impax Laboratories and Endo Pharmaceuticals that the FTC claims illegally kept a generic version of the opioid pain medication Opana ER off the market.